KCM
IONS icon

Kennedy Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Kennedy Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.4M Buy
111,830
+2,539
+2% +$200K 0.18% 195
2025
Q4 		$8.65M Sell
109,291
-13,475
-11% -$1.01M 0.18% 188
2025
Q3 		$8.03M Sell
122,766
-9,279
-7% -$453K 0.18% 209
2025
Q2 		$5.22M Sell
132,045
-18,379
-12% -$601K 0.12% 285
2025
Q1 		$4.54M Sell
150,424
-72,854
-33% -$2.39M 0.11% 302
2024
Q4 		$7.81M Buy
223,278
+61,202
+38% +$2.29M 0.17% 198
2024
Q3 		$6.49M Sell
162,076
-92,267
-36% -$4.29M 0.14% 249
2024
Q2 		$12.1M Buy
254,343
+4,816
+2% +$198K 0.26% 117
2024
Q1 		$10.8M Buy
249,527
+21,102
+9% +$1.01M 0.22% 154
2023
Q4 		$11.6M Sell
228,425
-10,210
-4% -$489K 0.25% 126
2023
Q3 		$10.8M Buy
238,635
+8,374
+4% +$345K 0.26% 111
2023
Q2 		$9.45M Buy
230,261
+47,836
+26% +$1.84M 0.22% 158
2023
Q1 		$6.52M Buy
182,425
+43,244
+31% +$1.62M 0.19% 197
2022
Q4 		$5.26M Sell
139,181
-5,614
-4% -$236K 0.15% 249
2022
Q3 		$6.4M Buy
144,795
+25,113
+21% +$1.06M 0.19% 187
2022
Q2 		$4.43M Buy
119,682
+109,834
+1,115% +$4.14M 0.12% 292
2022
Q1 		$365K Buy
9,848
+2,315
+31% +$75.8K 0.01% 569
2021
Q4 		$229K Sell
7,533
-531
-7% -$16.7K ﹤0.01% 600
2021
Q3 		$270K Sell
8,064
-265
-3% -$9.98K 0.01% 612
2021
Q2 		$332K Buy
8,329
+321
+4% +$12.6K 0.01% 604
2021
Q1 		$360K Buy
8,008
+1,797
+29% +$100K 0.01% 633
2020
Q4 		$351K Buy
+6,211
New +$310K 0.01% 612
2017
Q1 		– Sell
-27,154
Closed -$1.3M – 742
2016
Q4 		$1.3M Sell
27,154
-22,846
-46% -$904K 0.02% 648
2016
Q3 		$1.83M Buy
+50,000
New +$1.56M 0.04% 587

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's IONS Position: Q1 2026 in Review

Kennedy Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 2.3% in Q1 2026, buying an estimated $200K and bringing the position to 111,830 shares worth $8.4M. The position accounts for 0.18% of the portfolio, ranked #195.

Kennedy Capital Management first reported a position in IONS in Q3 2016 and has held it in 24 quarters since. The position peaked at $12.1M in Q2 2024. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Kennedy Capital Management held 111,830 shares of Ionis Pharmaceuticals worth $8.4M as of Q1 2026.
  • Kennedy Capital Management bought 2,539 Ionis Pharmaceuticals shares in Q1 2026, an estimated $200K.
  • Ionis Pharmaceuticals made up 0.18% of Kennedy Capital Management's portfolio in Q1 2026, its #195 holding.
  • Kennedy Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 24 quarters since.
  • Kennedy Capital Management's Ionis Pharmaceuticals position peaked at $12.1M in Q2 2024.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.